Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  London Stock Exchange  >  Progressive Digital Media Group PLC       GB00B1GCQP32

PROGRESSIVE DIGITAL MEDIA GROUP PLC
Mes dernières consult.
Most popular
  Report  
SummaryNewsCalendarCompanyFinancialsRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets
OFFRE ETE Zonebourse : Jusqu'à 6 mois offerts sur tous les portefeuilles

GlobalData : Global HER2-positive breast cancer market to face challenges from biosimilars through to 2025

share with twitter share with LinkedIn share with facebook
share via e-mail
0
08/01/2017 | 05:11pm CEST

The human epidermal growth factor receptor type 2 (HER2)-positive breast cancer space across the eight major markets of the US, France, Germany, Italy, Spain, the UK, Japan, and China, which is set to hit $9.89 billion in 2025, is likely to face barriers due to the introduction of new biosimilars, according to research and consulting firm GlobalData.

The company's latest report states that the long-anticipated launch of oncology biosimilars in 2017 will be closely watched as drug makers expect to struggle with biosimilar erosion of their own biologics. In the HER-2-positive breast cancer market, the EU and Japan patents protecting Herceptin expired in 2014, meaning that biosimilar trastuzumab can enter the marketplace, while the drug's patent in the US will not expire until 2019.

Maxime Bourgognon, Ph.D., PharmD, Senior Healthcare Analyst for GlobalData explains: 'Trastuzumab biosimilars are now under review with the EMA and FDA, and the first biosimilar was filed for approval in Japan in April 2017. Considering the generally high uptake of biosimilars in the European markets, the launch of trastuzumab biosimilars is expected to have a significant effect on the market landscape.

'While physicians across all markets remain cautious when extrapolating clinical bioequivalence data, payers are expected to support switching to the cheaper alternative. Despite the growing portfolio of other HER2-targeted agents, this could be the first significant challenge to Roche's stronghold on the market.'

However, GlobalData believes the impact that trastuzumab biosimilars will have on the HER2-positive breast cancer space could be limited in markets where subcutaneous Herceptin was already sold at a cheaper price to its intravenous counterpart.

Bourgognon continues: 'Biosimilars are expected to have a negative effect on drug sales in established markets where Herceptin use has reached saturation. However, in China, where the high cost of Herceptin has hindered patient access, the launch of trastuzumab is expected to encourage more widespread use of the drug in in HER2-positive breast cancer care.'

- Information based on GlobalData's report: Pharmapoint: HER2-Positive Breast Cancer - Global Drug Forecast and Market Analysis to 2025.

GlobalData plc published this content on 01 August 2017 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 01 August 2017 15:11:02 UTC.

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on PROGRESSIVE DIGITAL MEDIA
06/13AFRICAS OIL AND GAS PROJECTS LEAD IN : GlobalData
AQ
06/13GLOBALDATA : Venezuela Wont Have Enough Oil To Export By 2019
AQ
06/12STUDY : Women more likely to use cash
AQ
06/09GLOBALDATA : LPWAN still has much to undertake
AQ
06/08GLOBALDATA : Women more likely than men to pay with cash
AQ
06/05GLOBALDATA : New Zealand`s suspension of offshore licensing unlikely to have imm..
AQ
06/05GLOBALDATA : 5G to usher in next wave of satellite communications
AQ
06/01GLOBALDATA : Brazilian pre-salt continues to deliver high productivity performan..
AQ
05/30GLOBALDATA : India, China and Indonesia set to see FDI inflows
AQ
05/29GLOBALDATA : ‘Global Commission’ Formed, as Tech Companies Attempt t..
AQ
More news
Financials ( GBP)
Sales 2018 154 M
EBIT 2018 -
Net income 2018 -
Debt 2018 53,7 M
Yield 2018 1,50%
P/E ratio 2018 -
P/E ratio 2019
EV / Sales 2018 4,92x
EV / Sales 2019 4,19x
Capitalization 703 M
Income Statement Evolution
Managers
NameTitle
Michael Thomas Danson Chief Executive Officer
Bernard Anthony Cragg Chairman
Graham Charles Lilley Chief Financial Officer & Secretary
Peter Martin Harkness Independent Non-Executive Director
Murray Legg Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
PROGRESSIVE DIGITAL MEDIA GROUP PLC933
S&P GLOBAL INC22.37%52 441
RELX N.V.-3.47%44 436
RELX-6.53%44 327
THOMSON REUTERS CORP-1.61%28 840
WOLTERS KLUWER10.79%16 235